XSHE002868
Market cap325mUSD
Jan 06, Last price
15.35CNY
1D
-5.54%
1Q
-8.69%
IPO
-12.11%
Name
Lifecome Biochemistry Co Ltd
Chart & Performance
P/E
—
P/S
4.71
EPS
—
Div Yield, %
1.02%
Shrs. gr., 5y
-0.33%
Rev. gr., 5y
8.05%
Revenues
507m
+53.71%
Net income
-222m
CFO
-187m
Dividend
May 21, 20210.14 CNY/sh
Earnings
May 20, 2025
Profile
Lifecome Biochemistry Co.,Ltd. operates as a biopharmaceutical company in China. It primarily offers bacitracin zinc products, colistin sulfate products, probiotics products, bacitracin methylene disalicylate products, biological preservatives, natamycin products, etc. The company was founded in 2003 and is based in Pucheng, China.
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|
| 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | 2015‑12 | |
| Income | |||||||||
Revenues | 507,005 53.71% | 329,850 -9.23% | |||||||
Cost of revenue | 666,451 | 377,690 | |||||||
Unusual Expense (Income) | |||||||||
NOPBT | (159,446) | (47,839) | |||||||
NOPBT Margin | |||||||||
Operating Taxes | (18,276) | ||||||||
Tax Rate | |||||||||
NOPAT | (141,170) | (47,839) | |||||||
Net income | (221,818) | ||||||||
Dividends | (24,224) | ||||||||
Dividend yield | 0.74% | ||||||||
Proceeds from repurchase of equity | 35,704 | ||||||||
BB yield | -1.09% | ||||||||
| Debt | |||||||||
Debt current | 437,033 | 251,378 | |||||||
Long-term debt | 563,759 | 150,963 | |||||||
Deferred revenue | 3,471 | 4,324 | |||||||
Other long-term liabilities | 85,150 | 44,999 | |||||||
Net debt | 871,653 | 330,007 | |||||||
| Cash flow | |||||||||
Cash from operating activities | (186,759) | ||||||||
CAPEX | (464,539) | ||||||||
Cash from investing activities | (254,250) | ||||||||
Cash from financing activities | 467,451 | 70,764 | |||||||
FCF | (396,228) | (21,791) | |||||||
| Balance | |||||||||
Cash | 84,385 | 23,761 | |||||||
Long term investments | 44,754 | 48,573 | |||||||
Excess cash | 103,788 | 55,841 | |||||||
Stockholders' equity | 73,639 | 291,255 | |||||||
Invested Capital | 1,393,129 | 948,347 | |||||||
ROIC | |||||||||
ROCE | |||||||||
| EV | |||||||||
Common stock shares outstanding | 154,040 | 153,404 | |||||||
Price | 21.26 -59.95% | 53.09 381.32% | |||||||
Market cap | 3,274,895 -59.79% | 8,144,236 381.32% | |||||||
EV | 4,149,371 | 8,477,854 | |||||||
EBITDA | (88,381) | 16,331 | |||||||
EV/EBITDA | 519.12 | ||||||||
Interest | 38,019 | 16,221 | |||||||
Interest/NOPBT | |||||||||